Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the interest coverage ratio high or low?
The interest coverage ratio of -23.08x is 66% below its 2-year average of -13.90x, around the middle of its 2-year range (-194.11x–183.60x).
As of the fiscal period ended Thursday, March 31, 2022. 607.10% below its 12-month average of 4.55x.
Reported quarterly interest coverage; no daily interpolation. Q1 FY2022 (2022-03-31): -23.08x.
INTEREST COVERAGE RATIO
-23.08x
INTEREST COVERAGE RATIO AVG TTM
4.55x
INTEREST COVERAGE RATIO AVG 3Y
-13.90x
INTEREST COVERAGE RATIO AVG 5Y
-13.90x
INTEREST COVERAGE RATIO AVG 10Y
49.38x
INTEREST COVERAGE RATIO AVG 15Y
51.26x
INTEREST COVERAGE RATIO AVG 20Y
49.61x
CURRENT VS TTM AVG
-607.10%
CURRENT VS 3Y AVG
-66.04%
CURRENT VS 5Y AVG
-66.04%
CURRENT VS 10Y AVG
-146.73%
CURRENT VS 15Y AVG
-145.02%
CURRENT VS 20Y AVG
-146.52%
SECTOR MEDIAN · HEALTHCARE
-3.98x
median of 336 covered companies
CURRENT VS SECTOR MEDIAN
-480.58%
vs the sector median at left
Anika Therapeutics, Inc.
Market Cap
$264.05M
Interest Coverage Ratio
-23.08x
TTM Avg
4.55x
3Y Avg
-13.90x
5Y Avg
-13.90x
Market Cap
$260.75M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$262.75M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$258.93M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$267.99M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$272.75M
Interest Coverage Ratio
-360.54x
TTM Avg
23.12x
3Y Avg
23.12x
5Y Avg
1139.56x
Market Cap
$251.01M
Interest Coverage Ratio
N/A
TTM Avg
0.97x
3Y Avg
1.45x
5Y Avg
67.07x
Market Cap
$249.24M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | INTEREST COVERAGE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anika Therapeutics, Inc. (ANIK) | $264.05M | -23.08x | 4.55x | -13.90x | -13.90x |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $260.75M | N/A | N/A | N/A | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $262.75M | N/A | N/A | N/A | N/A |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $258.93M | N/A | N/A | N/A | N/A |
| Century Therapeutics, Inc. (IPSC)vs › | $267.99M | N/A | N/A | N/A | N/A |
| AC Immune S.A. (ACIU)vs › | $272.75M | -360.54x | 23.12x | 23.12x | 1139.56x |
| Invivyd, Inc. (IVVD)vs › | $247.47M | N/A | N/A | N/A | N/A |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $251.01M | N/A | 0.97x | 1.45x | 67.07x |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $249.24M | N/A | N/A | N/A | N/A |
| Aurora Cannabis Inc. (ACB)vs › | $279.05M | -25.79x | 0.59x | 0.59x | 0.59x |
Interest Coverage
-23.1x
Debt/Equity
0.17
Current Ratio
4.48
Formula: Interest Coverage = EBIT / Interest Expense
Reference ranges:
Note: Interest coverage should be compared with historical interest expense, operating income, and industry capital structure.
Interest Coverage = EBIT / Interest Expense
The interest coverage ratio measures operating earnings relative to interest expense.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | INTEREST COVERAGE RATIO |
|---|---|
| 2022-03-31 | -23.08x |
| 2021-12-31 | -194.11x |
| 2021-09-30 | 27.08x |
| 2021-06-30 | 183.60x |
| 2021-03-31 | 29.26x |
| 2020-12-31 | -59.84x |
| 2020-09-30 | -26.42x |
| 2020-06-30 | -47.68x |
| 2013-12-31 | 31.56x |
| 2013-09-30 | 236.66x |
| 2013-06-30 | 258.34x |
| 2013-03-31 | 126.69x |
| 2012-12-31 | 3.02x |
| 2012-09-30 | 60.38x |
| 2012-06-30 | 124.85x |
| 2012-03-31 | 59.82x |
| 2011-12-31 | 98.48x |
| 2011-09-30 | 104.12x |
| 2011-06-30 | 81.22x |
| 2011-03-31 | 13.60x |
| 2010-12-31 | 54.44x |
| 2010-09-30 | 52.09x |
| 2010-06-30 | 30.43x |
| 2010-03-31 | 23.59x |
| 2009-12-31 | 0.73x |
| 2009-09-30 | 45.72x |
| 2009-06-30 | 873.90x |
| 2002-12-31 | 10.00x |
